Melissa B, Epperly
Director · 10 filings · Latest: Oct 1, 2026
Nautilus Biotechnology, Inc.
Roivant Sciences Ltd.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
ROIV | Melissa B, Epperly | Director | Oct 1, 2026 | Sale | $36.10 | 17,750 | $640.9K | 14,954 | |
ROIV | Melissa B, Epperly | Director | Oct 1, 2026 | Option Exercise | $4.46 | 17,750 | $79.2K | 32,704 | |
ROIV | Melissa B, Epperly | Director | Sep 15, 2026 | Sale | $39.74 | 4,938 | $196.2K | 9,900 | |
ROIV | MELISSA EPPERLY | — | Sep 15, 2026 | Proposed Sale | $41.02 | 22,688 | $930.7K | — | |
ROIV | Melissa B, Epperly | Director | Jun 29, 2026 | Sale | $34.38 | 17,750 | $610.3K | 16,474 | |
ROIV | Melissa B, Epperly | Director | Jun 29, 2026 | Option Exercise | $4.46 | 17,750 | $79.2K | 34,224 | |
ROIV | MELISSA EPPERLY | — | Jun 29, 2026 | Proposed Sale | $34.07 | 17,750 | $604.7K | — | |
ROIV | Melissa B, Epperly | Director | Mar 16, 2026 | Sale | $28.68 | 41,861 | $1.2M | 15,804 | |
ROIV | MELISSA B EPPERLY | — | Mar 16, 2026 | Proposed Sale | $28.68 | 41,861 | $1.2M | — |